title: Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response.
abstract: Adherence to tyrosine kinase inhibitor treatment is a significant factor in the achievement of a good clinical response in chronic myeloid leukemia (CML). The aim of this retrospective study is to investigate 1- and 2-year medication adherence to imatinib treatment, linking adherence rates with the clinical outcome, in accordance with European LeukemiaNet Recommendations for the management of CML. We have tried to find a cutoff value for adherence in order to achieve a good clinical outcome.
  
  
  
  The method used to calculate medication adherence was the ratio between the received and the prescribed daily dose.
  
  
  
  We observed the levels of mean adherence for each of the following response groups (in years 1 and 2, respectively): complete response (0.96, 0.95), MR4.5 (1.00, -), MR4 (0.93, 0.91), major molecular responses (0.96, 0.97), warning (0.91, 0.89) and failure (0.79, 0.84).
  
  
  
  Results show that the higher the adherence, the lower the level of BCR-ABL1. Furthermore, using cutoffs ≥0.9, outcomes were significantly improved compared to those with cutoffs <0.90. This value of adherence is in line with previous publications.
authors.affiliation: Hospital Pharmacy, Spirito Santo General Hospital of Pescara, Pescara, Italy.
authors.forename: Fiorenzo
authors.initials: F
authors.lastname: Santoleri
authors.forename: Ruggero
authors.initials: R
authors.lastname: Lasala
authors.forename: Elena
authors.initials: E
authors.lastname: Ranucci
authors.forename: Gaetano
authors.initials: G
authors.lastname: La Barba
authors.forename: Roberto
authors.initials: R
authors.lastname: Di Lorenzo
authors.forename: Antonio
authors.initials: A
authors.lastname: Vetrò
authors.forename: Paolo
authors.initials: P
authors.lastname: Di Bartolomeo
authors.forename: Alberto
authors.initials: A
authors.lastname: Costantini
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D055118:Medication Adherence; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl